Venture capitalists willing to take a risk on a dicey venture like developing a new drug and angel investors with a personal stake in developing a new, potentially life-saving product could provide better financial resources.
Management selection
The choice of 'C' reflects the high-level scientific knowledge required to create a new drug and the equally profound need to solicit and wisely use financial resources during the development process. Management should also know how to navigate the potential bureaucratic red tape a new drug is likely to encounter before government approval....
Academically-driven scientists may not understand how to 'pitch' the drug to investors, or even to explain the drug's utility to laypersons in Congress, when soliciting funding or regulatory approval. However, the most potentially damaging management team would be that of young MBAs with little knowledge of the lengthy nature of the drug development process. They might show frustration with the long duration of the necessary clinical trials to ensure patient safety and FDA approval, or urge the creation of an unethical marketing campaign that made unsubstantiated claims for the drug's potential benefits.
